|1.||Konopa, Jerzy: 4 articles (07/2012 - 01/2007)|
|2.||Niemira, Magdalena: 3 articles (11/2014 - 07/2012)|
|3.||Augustin, Ewa: 3 articles (11/2014 - 05/2010)|
|4.||Mazerska, Zofia: 3 articles (11/2014 - 07/2012)|
|5.||Ashok, Badithe T: 3 articles (10/2007 - 09/2005)|
|6.||Chen, Yuangen: 2 articles (10/2007 - 01/2007)|
|7.||Tiwari, Raj K: 2 articles (10/2007 - 01/2007)|
|8.||Banerjee, Debabrata: 2 articles (10/2007 - 01/2007)|
|9.||Tadi, Kiranmayi: 2 articles (10/2007 - 01/2007)|
|10.||Hołownia, Adam: 1 article (11/2014)|
09/16/2005 - "The introduction of a methyl group at C-4 resulted in C-1748, which has a significantly higher therapeutic efficacy and is being clinically developed as an anticancer agent for solid tumors. "
08/29/2006 - "Pre-clinical toxicology and pathology of 9-(2'-hydroxyethylamino)-4-methyl-1-nitroacridine (C-1748), a novel anti-cancer agent in male Beagle dogs."
10/01/2007 - "In xenograft studies, administration of C-1748 intra-peritoneally inhibited tumor growth by 80-90% with minimal toxicity. "
09/16/2005 - "The present study was undertaken to correlate the mutagenicity of C-857, C-1748, C-1790, C-1872 and C-1873 with their cytotoxicity and their anti-tumor efficacy. "
10/01/2007 - "C-1748, a DNA intercalating agent has been derived from its precursor C-857 that was a potent anti-cancer drug, but failed clinical development due to "high" systemic toxicities. "
|2.||Prostatic Neoplasms (Prostate Cancer)
09/16/2005 - "These studies demonstrate that C-1748 has the least mutagenic potential, with a much higher antitumor effect in prostate cancer and is a promising chemotherapeutic agent for clinical development."
01/01/2007 - "We are developing a 1-nitroacridine derivative, 9-(2'-hydroxyethylamino)-4-methyl-1-nitroacridine (C-1748), as an effective chemotherapeutic agent for prostate cancer. "
01/01/2007 - "C-1748 demonstrates high antitumor efficacy against human prostate cancer xenografts with markedly low mutagenicity and toxicity in dogs compared with its parent 9-(2'-hydroxyethylamino)-1-nitroacridine (C-857). "
01/01/2007 - "A surprising feature of C-1748 is the 40-fold difference in 50% inhibitory concentration between DU145 prostate cancer and HL-60 leukemia cells. "
07/15/2013 - "These effects are hypoxia-inhibited only in the case of C-1748, which is sensitive to P450 metabolism. "
07/01/2012 - "Compared with metabolism under normoxia, cellular metabolism under hypoxia led to higher levels of 1-aminoacridine and aza-acridine derivatives of both compounds and of the 6-membered ring metabolite of C-1748. "
07/01/2012 - "We investigated the metabolites of C-1748 and C-857 formed in rat and human liver microsomes, with human P450 reductase (POR) and in HepG2 cells under normoxia and hypoxia. "
07/15/2013 - "Pregnane X receptor dependent up-regulation of CYP2C9 and CYP3A4 in tumor cells by antitumor acridine agents, C-1748 and C-1305, selectively diminished under hypoxia."
05/01/2010 - "Antitumor 1-nitroacridine derivative C-1748, induces apoptosis, necrosis or senescence in human colon carcinoma HCT8 and HT29 cells."
05/01/2010 - "Moreover, prolonged drug incubation (up to 168h) resulted in massive detachment of cells from culture plates, which together with Annexin V/PI results, indicated that necrosis was the main response of HT29 cells to C-1748 treatment. "
|2.||A-Form DNA (A-DNA)
|4.||Reactive Oxygen Species (Oxygen Radicals)
|7.||pregnane X receptor
|1.||Heterologous Transplantation (Xenotransplantation)